Nielsen Kirk G.
Nielsen Kirk G.'s purchase track record
How the stock did after each of Nielsen Kirk G.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/9/2026 | SGP | $2.64M | -9.2% | -3.9% | +11.3% |
| 5/12/2025 | CVRX | $1.04M | +58.1% | +103.6% | +16.9% |
| 5/19/2022 | CVRX | $186K | +61.0% | +144.2% | +1.2% |
| 4/28/2022 | CVRX | $625K | +14.6% | +53.0% | -11.2% |
| 2/18/2022 | CVRX | $864K | -34.5% | -1.9% | -2.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.
Transaction History
| CVRX | ▲ Buy | Grant | 8,720 | $0 | 6/1/2026 | View on chart |
| SGP | ▼ Sell | Other | 548,067 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 359,255 | — | 2/9/2026 | View on chart |
| SGP | ▲ Buy | Open Market | 165,000 | $2.6M | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 548,067 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 1,690,230 | — | 2/9/2026 | View on chart |
| CVRX | ▲ Buy | Open Market | 10,966 | $60K | 5/15/2025 | View on chart |
| CVRX | ▲ Buy | Open Market | 61,200 | $320K | 5/14/2025 | View on chart |
| CVRX | ▲ Buy | Open Market | 101,413 | $536K | 5/13/2025 | View on chart |
| CVRX | ▲ Buy | Open Market | 25,200 | $121K | 5/12/2025 | View on chart |
| CVRX | ▲ Buy | Open Market | 8,070 | $41K | 5/24/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 4,432 | $22K | 5/23/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 13,387 | $67K | 5/20/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 10,976 | $55K | 5/19/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 3,992 | $24K | 5/5/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 25,503 | $153K | 5/4/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 32,809 | $197K | 5/3/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 41,988 | $251K | 5/2/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 100 | $597 | 4/28/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 3,400 | $28K | 2/24/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 38,200 | $307K | 2/23/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 40,008 | $318K | 2/22/2022 | View on chart |
| CVRX | ▲ Buy | Open Market | 26,659 | $211K | 2/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CVRx Appoints John Landry as CFO
CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.
CVRx Appoints John Landry as CFO. CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.